ToolsCalculators
Khorana Risk Score for Venous Thromboembolism in Cancer Patients
Predicts chemotherapy-associated VTE risk from tumour site and pre-chemotherapy labs.
Khorana Risk Score for Venous Thromboembolism in Cancer Patients
Primary tumour site
Pre-chemotherapy platelet count >=350 x 10^9/L
Hemoglobin <10 g/dL, or use of erythropoiesis-stimulating agents
Pre-chemotherapy leukocyte count >11 x 10^9/L
BMI >=35 kg/m^2
Result0 points
Low-risk for chemotherapy-associated venous thromboembolism.
- VTE risk group
- Low
When to use
- Estimating VTE risk before starting chemotherapy to inform discussion or use of pharmacologic thromboprophylaxis in ambulatory cancer patients.
Formula
Points: cancer site (stomach/pancreas = 2; lung, lymphoma, gynaecologic, bladder, testicular = 1; other = 0); platelets >=350x10^9/L = 1; hemoglobin <10 g/dL or ESA use = 1; leukocytes >11x10^9/L = 1; BMI >=35 = 1. Low 0, Intermediate 1-2, High >=3.
Pearls and pitfalls
- Derived and validated in ambulatory patients about to start systemic chemotherapy, not hospitalised patients.